GC Noksipja Joins CEPI-Led Tabletop Exercise to Prepare for Future Pandemics

Verifying the feasibility of vaccine supply within 100 days
using an mRNA platform

GC Noksipja announced on the 9th that it had participated in the "Korea 100Day Mission Tabletop Exercise" held over two days from the 5th to the 6th, organized by the Coalition for Epidemic Preparedness Innovations (CEPI), the Korea Disease Control and Prevention Agency, the Ministry of Food and Drug Safety, and the International Vaccine Institute (IVI).

This tabletop exercise assumed the occurrence of a future pandemic (a worldwide outbreak of infectious disease) and used scenario-based simulations to verify whether the entire process from vaccine development to approval, manufacturing, and supply could be completed within 100 days. In addition, it was conducted with the aim of minimizing the risk of response delays in an actual pandemic situation by pre-establishing decision-making systems among the government, international organizations, and vaccine manufacturers.

A view of the GC Green Cross headquarters in Yongin, Gyeonggi Province. GC Green Cross

GC Noksipja participated as a manufacturer capable of carrying out the full process of developing mRNA (messenger ribonucleic acid) medicines and reviewed its capabilities in vaccine development and production using its own mRNA platform. During this process, participants also discussed flexible application measures for clinical and approval procedures in a pandemic situation, and through this, the company expects that more immediate responses will be possible through close cooperation with the government.

Furthermore, GC Noksipja expects that, based on its vaccine development capabilities demonstrated through this tabletop exercise, opportunities for future cooperation with international organizations in vaccine development and procurement will also expand.

Lee Jaewoo, Head of Development at GC Noksipja, said, "This tabletop exercise served as an opportunity to review GC Noksipja's role and response capabilities in a future pandemic situation," adding, "We will continue to actively participate in public-private cooperation to respond to global health crises and contribute to strengthening the public health safety net."

Meanwhile, GC Noksipja completed the first subject dosing in a Phase 1 clinical trial of a COVID-19 mRNA vaccine in January last year, and plans to submit a Phase 2 clinical trial IND in the second half of this year.